UNITED STATES SECURITIES AND EXCHANGE COMMISSION August 14, 2015

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

Intec Pharma Ltd.

File No. 333-204836 - CF#32621

Intec Pharma Ltd. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the exhibits to a Form F-1 registration statement filed on June 9, 2015, as amended.

Based on representations by Intec Pharma Ltd. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1	through June 1, 2025
Exhibit 10.2	through June 1, 2025
Exhibit 10.17	through June 1, 2025
Exhibit 10.18	through June 1, 2025

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary